Biolex | Wikipedia audio article
Channel: wikipedia tts
Date: 2019-03-29

This is an audio version of the Wikipedia Article:
https://en.wikipedia.org/wiki/Biolex





Listening is a more natural way of learning, when compared to reading. Written language only began at around 3200 BC, but spoken language has existed long ago.

Learning by listening is a great way to:
- increases imagination and understanding
- improves your listening skills
- improves your own spoken accent
- learn while on the move
- reduce eye strain

Now learn the vast amount of general knowledge available on Wikipedia through audio (audio article). You could even learn subconsciously by playing the audio while you are sleeping! If you are planning to listen a lot, you could try using a bone conduction headphone, or a standard speaker instead of an earphone.

Listen on Google Assistant through Extra Audio:
https://assistant.google.com/services/invoke/uid/0000001a130b3f91
Other Wikipedia audio articles at:
https://www.youtube.com/results?search_query=wikipedia+tts
Upload your own Wikipedia articles through:
https://github.com/nodef/wikipedia-tts
Speaking Rate: 0.9471977693790306
Voice name: en-GB-Wavenet-C


"I cannot teach anybody anything, I can only make them think."
- Socrates


SUMMARY
=======
Biolex Therapeutics was a biotechnology firm in the Research Triangle of North Carolina that was founded in 1997 and raised $190 million from investors.  It filed for  Chapter 7 bankruptcy on July 5, 2012.The company focused on expression of difficult-to-synthesize recombinant proteins in its LEX platform, which used Lemna, a duckweed.  The duckweeds are a family of small aquatic plants that can be grown in sterile culture.  Biolex developed recombinant DNA technology for efficiently producing pharmaceutical proteins in Lemna.  Therapeutic glycosylated proteins, including monoclonal antibodies and interferon (IFN-alpha2b) have been produced using the LEX platform.
Biolex acquired Epicyte Pharmaceutical Inc. on May 6, 2004, and acquired LemnaGene SA of Lyon, France in 2005. Biolex was a privately held company, originally backed by Quaker BioVentures, The Trelys Funds, and Polaris Venture Partners.  The term "plantibody" is trademarked by Biolex.  In May 2012 Biolex announced that it sold the LEX System to Synthon, a Netherlands-based specialty pharmaceutical company. The sale included two preclinical biologics made with the LEX System, BLX-301, a humanized and glyco-optimized anti-CD20 antibody for non-Hodgkin's B-cell lymphoma and other B-cell malignancies and BLX-155, a direct-acting thrombolytic.  The financial terms of the sale were not disclosed.